m pharm tdds
TRANSCRIPT
Transdermal drug delivery systemTransdermal drug delivery systemTransdermal drug delivery systemTransdermal drug delivery system
Transdermal Therapeutic Systems
vDiffusion of the medication (drug) through skin into
the systemic circulation for distribution and
therapeutic effect
2
therapeutic effect
vMost TDD systems use passive delivery
13.1 Advantages of TTS’s
1. Eliminates oral absorption variables.
2. Eliminates first-pass metabolism
3. Provides controlled constant drug.
4. Can accommodate potent drugs
33
4. Can accommodate potent drugs
5. Permits self-administration
6. Non-invasive (no needles or injections)
7. Improves patient compliance
8. Easy treatment termination
Limitations of TDD Systems
• Poor diffusion of large molecules• Skin irritation
4
• Therapeutic indication• Desired drug delivery profile
- Dose level, duration, etc.• Skin adhesion profile• Application site
TDD System Design Factors
5
• Application site• Ease of application• Patch size, shape, appearance, comfort• Wear period• Packaging• Patch disposal• Patch cost
6
Process of transdermal permeation.
BASIC COMPONENTS OF TDDS1.Polymer matrix2.The drug 3.Permeation enhancers4.Other excipients
1.Polymer matrixIdeal polymer
٠MWT,and chemical functionality of the polymer should not affect the diffusivity of drug and its release
7
٠stable٠non reactive٠easily manufactured٠easily fabricated into desired product٠inexpensive٠degaradation product must be non toxic or non antagonistic to the host٠ should retain its mechanical properties when the large amount of drug is
loaded in to it
Polymers used in TDDS• Natural polymers
– Cellulose derivatives– Zein– Gelatin– Shellac– Waxes– Proteins– Gums– Natural rubbers– starch
8
• Synthetic elastomers--polybutadiene--hydrin rubber--polysiloxone--silicone rubber--nitrile--acrylonitrile--butyl rubber--styrene butadiene rubber--neoprine etc.
• Synthetic polymersPVA,PVC,PE,PP,Poly amide,Poly acrylate,Polyurea,PVP,PMMA,Epoxy etc.
2. Suitable drug candidate• Physico chemical properties of drug
– Should have MW less than 1000 daltons(500-1000)– Should have affinity for both lipophilic and hydrophilic phases– Should have low melting pont
• Biological properties of drug– Should be potent(less than 20mg)– Half life should be short
9
– Half life should be short– Must not induce a cutaneous irritant or allergic response– Drugs which degrade in the GI tract or inactivated by hepatic
first pass effect are suitable candidate– Tolerance to the drug must not develop – Drugs which has to be administered for a longer period of time
can be formulated – Drugs which cause adverse effects to non target tissues can
also be formulated
3.PERMEATION ENHANCERS(to enhance stratum corneum permeability)
• SolventsIncreases penetration by swelling the polar pathway transport or fluidising lipidsEg.water,ethanol,methanol,DMS,homologs of methyl sulphoxide,dimethyl acetamide,and DMF,2-pyrrolidone,N-methyl,2-pyrrolidone,laurocapram,PG,glycerol,silicone fluids,isopropyl palmitate.
• SurfactantsEnhances the polar pathway transport of hydrophilic drugs
• Anionic surfactantsDioctyl sulpho succinate,SLS,deco decylmethyl sulphoxide etc.
10
Dioctyl sulpho succinate,SLS,deco decylmethyl sulphoxide etc.• Non ionic surfactants
Pluronic F127,Pluronic F68,etc.• Bile salts
Sodium taurocholate,sodium deoxy cholate,sodium tauroglycocholate.• Binary systems
Propylene glucol-oleic acid and 1,4-butane diol-linoleic acid• Miscellaneous
Urea-hydrating and keratolytic agent,N,N-dimethyl-m-toluamide,calcium thioglycolate,anti cholinergic agents
• Potential permetion enhancersEuclyptol,di-o-methyl-ß-cyclodextrin and soyabean casein
Permeability Coefficient Is the Critical Predictor of Transdermal Delivery
Transport = Flux = (mg/cm2/sec) = P x A x (Cd – Cr)
Permeability Coefficient = P = D x K (cm/sec) h
11
Where A = Surface area of patchD = Diffusivity of drug in membrane (skin)K = Partition coefficient (patch/skin)C = Concentration in donor or receptor
(patch or skin)h = Thickness of membrane (skin)
4.OTHER EXCIPIENTS• AdhesivesIdeal properties• Should not irritate or sensitize the skin or affect normal functions of the skin• Should adhere to the skin aggressively• Should be easily removed• Should not leave an un washable residue on the skin• Should have an intimate contact with the skin • Should be compatible with the drug,excipients and permeation enhancers
12
• Permeation of drug should not be affected• Backing membraneIdeal properties• Flexible and provide good bond to the drug reservoir• Prevent drug from leaving the dosage form• Should be impermeable• E.g.metallic plastic laminate,plastic backing with absorbent pad and
occlusive base plate,adhesive foam pad with occlusive base plate.
• Liner: Protects the drug during storage and is removed prior to use
• Drug• Adhesive: Serves to bind the components
of the patch to the skin• Membrane: Controls the release of the
13
• Membrane: Controls the release of the drug from the reservoir in certain types of patches
• Backing: Protects the patch from the outer environment.
Formulation of TDDS1.Membrane-moderated or permeation controlled TDDS
• Drug reservoir(homogenous dispersion of drug with polymeric matrix or suspension of drug in un leachable viscous liquid medium such as silicone fluid) is encapsulated within drug impermeable metallic plastic laminate and a rate controlling polymeric membrane(ethylene vinyl acetate co polymer)
• The cross sectional view of this system is shown in the following Fig.1
14
Reservoir Patches
15
• The reservoir system has a drug layer that is separate from the adhesive.
Film Backing
Drug Layer
Schematic Drawing of the Reservoir type of patch.
Rate-controlling Membrane
16
Protective Peel Strip (removed prior to use)
skin
Contact Adhesive
Example of this system are1.Nitro glycerin releasing TDDS (Transderm-
Nitro/ciba,USA)for once a day medication in angina pectoris
2.Scopolamine releasing TDDS (Transderm-Scop/ciba,USA)for 72 hrs.prophylaxis of motion sickness
3. Estradiol releasing TDDS (Estraderm/ciba)for treatment
17
3. Estradiol releasing TDDS (Estraderm/ciba)for treatment of menopausal syndrome
4. Clonidine releasing TDDS (Catapres/Boehringer Ingelheim)for 7 day therapy of hyper tension
5. Prostaglandin-derivatives TDDS
2.Adhesive diffusion/dispersion-controlled TDDS
Drug reservoir• homogenous dispersion of drug with adhesive polymer(poly(isobutylene) or
poly acrylate)
• Then spreading of this medicated adhesive polymer on flat sheet of drug impermeable metallic plastic backing to form thin drug reservoir layer
• On top of the drug reservoir layer,thin layers of rate controlling adhesive polymer of specific permeability and constant thickness are applied to produce an adhesive diffusion/dispersion-controlled TDDS
18
polymer of specific permeability and constant thickness are applied to produce an adhesive diffusion/dispersion-controlled TDDS
• The cross sectional view of this system is shown in the following Fig.2
Drug in Adhesive Patches
• A system in which the drug is incorporated directly into the adhesive, rather than into a separate layer. Usually used for smaller
19
a separate layer. Usually used for smaller molecular weight compounds.
• These can be either a single layer or multi-layer.
• Sometimes referred to as the “matrix type patch”
Film Backing
Drug/Adhesive Layer
Schematic Drawing of the Matrix (Drug-in-Adhesive) type of patch.
20
Drug/Adhesive Layer
Protective Liner (removed prior to use)
skin
Examples for this system1.Iso sorbide dinitrate-releasing
TDDS
21
TDDS 2.Verapamil releasing TDDS
• 3.Matrix diffusion-controlled TDDS
Drug reservoir
• homogenous dispersion of drug with hydrophilic or lipophilic polymer matrix by any one of the following methods
• Homogenous dispersion of finely ground drug particles with liquid polymer or highly viscous base polymer followed by cross linking of polymer chains
• Homogenous mixing of drug solid with rubbery polymer at an elevated temperature
22
• Homogenous mixing of drug solid with rubbery polymer at an elevated temperature
• Dissolving the drug and polymer in a common solvent follwed by solvent evaporation in a mould at an elevated temperature or under vaccum.
• Medicated polymer is moulded in to desired surface area and controlled thickness
• This medicated polymer disc is pasted on to an occlusive base plate with impermeable plastic backing
• Then the adhesive polymer is spread along the circumference to form a strip of adhesive rim around the medicated disc
Example of this system are
1.Nitro glycerin releasing TDDS (Nitro-Dur and Nitro-Dur II /Key pharmaceuticals,USA)
2. Estradiol di acetate releasing TDDS
3. Verapamil releasing TDDS
The cross sectional view of this system is shown in the following Fig.3
23
4.Micro reservoir type/micro sealed dissolution-controlled TDDS
Combination of the reservoir and matrix diffusionDrug reservoir•suspension of drug with aqueous solution of water soluble liquid polymer
•Homogenous dispersion of drug suspension in a lipophilic polymer(silicone elastomer)
•As a result discrete un leachable microscopic spheres of drug reservoir is formed which is stabilized by cross linking
•Medicated polymer is moulded in to desired surface area and controlled thickness and it is coated with
24
•Medicated polymer is moulded in to desired surface area and controlled thickness and it is coated with a layer of bio compatible polymer to modify mechanism and rate of drug release
•This medicated polymer disc is pasted on to an occlusive base plate with impermeable plastic backing
•Then the adhesive polymer is spread along the circumference to form a strip of adhesive rim around the medicated disc
Example of this system are
1.Nitro glycerin releasing TDDS (Nitrodisc /searle,USA)
The cross sectional view of this system is shown in the following Fig.4
25
Products on the market, or in development include:
• Clonidine• Works as an agonist of adrenaline at the
presynaptic α2 adrenergic • Product name = Catapres-TTS®
• used to treat hypertension
26
• used to treat hypertension
• Ethinylestradiol (EO) and norelgestromin (N)• Product name = Ortho-Evra®
• Used for Contraception• Type of patch = Drug-in-Adhesive• Frequency of application = weekly
27
OH
H
H H
Ethinylestradiol (an estrogen)
HO
• Fentanyl• Product Name = Duragesic®
• Used for: Analgesia• Type of Patch = Drug-in-Adhesive• Frequency of Application = Weekly
28
N
O
N
• Lidocaine• Product Name = Lidoderm®
• Used for: analgesia of postheretic neuralgia (PHN), a painful condition caused by the varicella zoster virus (herpes zoster = shingles)
• Type of Patch = Reservoir• Frequency of Application = Daily
29
• Frequency of Application = Daily
• Nicotine• Product name = Habitrol®, Nicoderm –
CQ®, Nicotrol®, Prostep®
• Used for: Smoking cessation• Frequency of administration = Daily
30
• Nitroglycerin• Works by producing nitric oxide (NO), which then acts as
a vasodilator• Product Names = Nitro-Dur®, Transderm-Nitro®
• Used for: Angina• Type of Patch = Nitro-Dur is Drug-in-adhesive
Nitrodisc is reservoir• Frequency of administration = Daily
31
• Frequency of administration = Daily
• Estradiol• Product Name = Alora®, Climara®, Esclim®,
Estraderm®, FemPatch®, Vivelle®, Vivelle-DOT®
• Used for: Hormone replacement• Type of Patch: Drug-in-adhesive• Frequency of application = weekly
32
• Estradiol + Norethindrone• Product name = CombiPatch®
• Used for: Hormone Replacement
33
O
OH
H H
H H
Norethindrone
• Oxybutynin• Works as competitive antagonist of the
muscarinic acetycholine receptor• Product name = Oxytrol®
• Used for: Overactive bladder (antispasmodic)• Type of Patch: Drug-in-adhesive• Frequency of application = twice a week
34
• Scopolamine• Works as competitive antagonist of acetylcholine
at the muscarinic receptor• Product Name = Transderm Scop®
• Used for: Motion Sickness
35
• Testosterone• Product Names = Androderm®, Testoderm
TTS®, Testoderm®
• Used for: Hypogonadism
36
• Lidocaine + Epinephrine• Product name = Lidosite• Used for: Dermal anesthesia• Type of Patch = Reservoir,
iontophoretic.
37
Epinephrine acts as vasoconstrictor, thus prolonging the duration of action of lidocaine (by delaying resorption) at the site
Manufacturer Trade name Drug Strength available
Ciba
Estraderm Estradiol 25 µg, 50 µg, 100 µg
Transderm-Scop Scopolamine 1.5 mg
Transderm-Nitro Nitroglycerin 0.1 mg, 0.2 mg
38
Janssen Duragesic Fentanyl 25 µg, 50 µg, 100 µg
Basel Habritol Nicotine 21 µg
Parke-Davis Nicotrol Nicotine 21 µg
Lederle Prostep Nicotine 21 µg
39
TTS Available in market
Large scale mfg of TTS
üPhysical parameters üEvaluation of adhesiveüIn-vitro testingüIn-vivo assessmentüCutaneous metabolism
Evaluation Parameters
4040
üCutaneous metabolismüStability studiesüEvaluation of skin reactions.
7/19/2012 40
Thickness
41417/19/2012 41
Weight variation
42427/19/2012 42
Folding endurance
43437/19/2012 43
Moisture content
% Moisture content = Initial weight – Final weight X 100
44447/19/2012 44
% Moisture content = Initial weight – Final weight X 100Final weight
Moisture uptake
% moisture uptake = Final weight – Initial weight X 100
45457/19/2012 45
Initial weight
Flatness
% constriction = I1 – I2 X 100I1
46467/19/2012 46
I2 = Final length of each stripI1 = Initial length of each strip
Drug content
47477/19/2012 47
Water Vapor Transmission studies
48487/19/2012 48
Evaluation of adhesive
1} Peel adhesion propertiesIt is the force required to remove adhesive from test substrate.
49497/19/2012 49
2} Tack properties
It is the ability of the polymer to adhere to substrate with little contact
pressure.
2.1} Thumb tack test
2.2} Rolling ball tack test
5050
2.2} Rolling ball tack test
7/19/2012 50
2.3}Quick-stick (or peel-tack) test
51517/19/2012 51
2.4} Probe tack test
52527/19/2012 52
3} Shear strength propertiesShear strength is the measurement of the cohesive strength of adhesive polymer.
53537/19/2012 53
Tensile strength
Tensile strength= F/a.b (1+L/l)
F - the force required to breaka - width of film
54547/19/2012 54
a - width of filmb - thickness of filmL - length of filml - elongation of film at break point
In-vitro testing
üThe Paddle over Disc
üThe Cylinder modified USP Basket
üThe reciprocating disc
5555
üDiffusion Cells e.g. Franz Diffusion Cell and its modification Keshary-
Chien Cell
7/19/2012 55
In-vitro testing
Importance
(1)Defining skin permeation kinetic studies using a diffusion cell system and cadaver skin during the drug
5656
diffusion cell system and cadaver skin during the drug development process.
(2) in vitro drug release kinetics, to be used for batch-to-batch release and as a compendial test.
7/19/2012 56
Preparation of skin for permeation studiesPreparation of skin for permeation studies
ll Intact Full thickness skinIntact Full thickness skinHair removal removal of subcutaneous Hair removal removal of subcutaneous
tissue dermis is cleaned with isopropyl tissue dermis is cleaned with isopropyl alcohol washed with water alcohol washed with water
5757
alcohol washed with water alcohol washed with water stored at stored at --2020°°CC
ll Separation of epidermis from full Separation of epidermis from full thickness skinthickness skin::
5858
K-C cell for permeation studies
7/19/2012 58
5959
Effect of skin uptake metabolismEffect of skin uptake metabolism
6060
In-vivo assessment
1} Animal model
Mouse, hairless rat, hairless dog, hairless rhesus monkey,
6161
Mouse, hairless rat, hairless dog, hairless rhesus monkey, rabbit, guinea pig
7/19/2012 61
In-vivo assessment
2} Human model
Ø. Phase I clinical trials are conducted to determine mainly safety in volunteers.
ØPhase II clinical trials determine short term safety and mainly effectiveness
6262
in patients.
Ø Phase III trials indicate the safety and effectiveness in large number of patient population.
ØPhase IV trials at post marketing surveillance are done for marketed
patches to detect adverse drug reactions.
7/19/2012 62
Skin irritation studiesSkin irritation studies
ll Group I was served as normal, without Group I was served as normal, without any treatment.any treatment.
ll Group II, control, was applied with Group II, control, was applied with
Contact dermatitis
6363
ll Group II, control, was applied with Group II, control, was applied with marketed adhesive tape.marketed adhesive tape.
ll Group III Transdermal systems (blank)Group III Transdermal systems (blank)ll Group IV Transdermal systems (drug Group IV Transdermal systems (drug loaded)loaded)
ll Group V standard irritant .Group V standard irritant .
Evaluation of skin reactions.
64647/19/2012 64
Stability studies
65657/19/2012 65
Study Storage conditions Time period
Temperature Relative humidity
Long Term 25°C± 2°C 60%± 5% 12 months
6666
Long Term 25°C± 2°C OR
30°C± 2°C
60%± 5% OR
65%± 5%
12 months
Intermediate 30°C± 2°C 65%± 5% 6 months
Accelerated 40°C± 2°C 75%± 5% 6 months
APPLICATIONS
6767
APPLICATIONS
7/19/2012 67
The Past
• 3000 BC--Pharmaceuticals and plasters first recorded in Babylonia.
• 1500 BC--Plasters recorded in the Ebers Papyrus (Egypt).
6868
Papyrus (Egypt). • Plasters made by physicians or pharmacists at
the time of dispensing
7/19/2012 68
The Past
• Used for topical and deep tissues• Counterirritants, protective dressings, belladonna,
salicylic acid, flaxseed, mustard,
Plasters, Poultices and CeratesPlasters, Poultices and Cerates
6969
salicylic acid, flaxseed, mustard, • Adhered to skin with stiff ointments, waxes,
melted waxes and rubber resins, kaolin• Applied hot, could absorb water• Backings made of cloth or animal skin
7/19/2012 69
The Past: Adhesives
Example of plaster formula (1909)Rubber 20 gramsPetrolatum 20 gramsLead Plaster 960 grams
7070
Lead Plaster 960 gramsTo make, 1000 grams
Add any one of the following Belladonna Leaves,Oleoresin of Capsicum, Mercury, Opium, Soap
7/19/2012 70
The Past
The last 150 years:• Electrically assisted applications first occurred
in late 1800s and in early 1900s.• Rubber became available in the 1800s
7171
• Rubber became available in the 1800s• Nitroglycerin was applied topically as an
ointment for delivery to the bloodstream in the 1950 to present.
• Belladonna, capsicum, mustard and salicylic acid plasters
7/19/2012 71
The Present Day
• 1970-- Alza Research (US) began first development of the modern transdermal
• 1980-- Scopolamine first transdermal reached US
7272
US • 2002– Many Rx and non-RX products in US
market.• Transdermals deliver drugs from a few hours
up to 7 days.
7/19/2012 72